Dr Reddy’s Laboratories and Hetero, along with other generic drug makers, enter into voluntary licensing agreements with Gilead Sciences to produce and distribute HIV drug Lenacapavir in India and 120 LMICs. Lenacapavir, which inhibits HIV at multiple stages, recently showed promising results in prevention trials.
Related Posts
GST hike on electric vehicles to hit adoption: Mercedes-Benz
Mercedes-Benz India warns that raising GST rates on electric vehicles above Rs 40 lakh could hinder investment, employment, and EV adoption. CEO Santosh Iyer argues […]
October inflation hits 6.21%, highest in over a year due to rising food costs
India’s retail inflation surged to 6.21 percent in October, exceeding the Reserve Bank of India’s target range for the first time in over a year. […]
Vadhvan Port: PM Modi to lay foundation stone for India’s largest deep-water port – top facts you shouldn’t miss
Prime Minister Narendra Modi will lay the foundation for the Vadhvan Port project in Maharashtra’s Palghar. Estimated to cost around Rs 76,000 crore, this project […]